cancer screening strategies in low-resource settings: clinical benefits and cost effectiveness. JAMA. 2001;285:3107-3115. 25. Crum CP. The beginning of the end for cervical cancer? N Engl J Med. 2002; 347:1703-1705. 26. Skjeldstad FE, Koustsky L; for theMerck Phase III HPV Vaccine Steering Com-mittee (FUTURE II). Phase III trial of prophylactic quadrivalent HPV 6, 11, 16, 18 L1 virus-like particle (VLP) vaccine: prevention of cervical intraepithelial neoplasia (CIN) 2/3 including adeno- and squamous-cell carcinoma in situ (CIS). Presented
No takes yet. Share an insight, caveat, or question.
Stuart Pocock (2005) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: